 |
|
|
|
|
|
 |
Contents |
 |
|
|
|
|
|
|
|
|
|
|
|
|
* Residue conservation analysis
|
|
|
|
|
|
|
|
|
|
|
|
Gene Ontology (GO) functional annotation
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cellular component
|
extracellular region
|
2 terms
|
|
|
Biological process
|
pathogenesis
|
1 term
|
|
|
Biochemical function
|
protein binding
|
2 terms
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
|
|
|
|
|
| |
|
DOI no:
|
Nature
385:833-838
(1997)
|
|
PubMed id:
|
|
|
|
|
|
| |
|
Crystal structure of the anthrax toxin protective antigen.
|
|
C.Petosa,
R.J.Collier,
K.R.Klimpel,
S.H.Leppla,
R.C.Liddington.
|
|
|
|
|
| |
ABSTRACT
|
|
|
|
| |
|
|
Protective antigen (PA) is the central component of the three-part protein toxin
secreted by Bacillus anthracis, the organism responsible for anthrax. After
proteolytic activation on the host cell surface, PA forms a membrane-inserting
heptamer that translocates the toxic enzymes, oedema factor and lethal factor,
into the cytosol. PA, which has a relative molecular mass of 83,000 (M(r) 83K),
can also translocate heterologous proteins, and is being evaluated for use as a
general protein delivery system. Here we report the crystal structure of
monomeric PA at 2.1 A resolution and the water-soluble heptamer at 4.5 A
resolution. The monomer is organized mainly into antiparallel beta-sheets and
has four domains: an amino-terminal domain (domain 1) containing two calcium
ions and the cleavage site for activating proteases; a heptamerization domain
(domain 2) containing a large flexible loop implicated in membrane insertion; a
small domain of unknown function (domain 3); and a carboxy-terminal
receptor-binding domain (domain 4). Removal of a 20K amino-terminal fragment
from domain 1 allows the assembly of the heptamer, a ring-shaped structure with
a negatively charged lumen, and exposes a large hydrophobic surface for binding
the toxic enzymes. We propose a model of pH-dependent membrane insertion
involving the formation of a porin-like, membrane-spanning beta-barrel.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
 |
 |
|
Literature references that cite this PDB file's key reference
|
|
|
| |
PubMed id
|
|
Reference
|
|
|
|
|
|
K.L.Thoren,
and
B.A.Krantz
(2011).
The unfolding story of anthrax toxin translocation.
|
| |
Mol Microbiol, 80,
588-595.
|
|
|
|
|
|
|
L.D.Jennings-Antipov,
L.Song,
and
R.J.Collier
(2011).
Interactions of anthrax lethal factor with protective antigen defined by site-directed spin labeling.
|
| |
Proc Natl Acad Sci U S A, 108,
1868-1873.
|
|
|
|
|
|
|
S.M.Opal,
Y.P.Lim,
P.Cristofaro,
A.W.Artenstein,
N.Kessimian,
D.Delsesto,
N.Parejo,
J.E.Palardy,
and
E.Siryaporn
(2011).
Inter-α inhibitor proteins: a novel therapeutic strategy for experimental anthrax infection.
|
| |
Shock, 35,
42-44.
|
|
|
|
|
|
|
A.F.Kintzer,
H.J.Sterling,
I.I.Tang,
E.R.Williams,
and
B.A.Krantz
(2010).
Anthrax toxin receptor drives protective antigen oligomerization and stabilizes the heptameric and octameric oligomer by a similar mechanism.
|
| |
PLoS One, 5,
e13888.
|
|
|
|
|
|
|
E.Yoshida,
M.Hidaka,
S.Fushinobu,
T.Koyanagi,
H.Minami,
H.Tamaki,
M.Kitaoka,
T.Katayama,
and
H.Kumagai
(2010).
Role of a PA14 domain in determining substrate specificity of a glycoside hydrolase family 3 β-glucosidase from Kluyveromyces marxianus.
|
| |
Biochem J, 431,
39-49.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
G.K.Feld,
K.L.Thoren,
A.F.Kintzer,
H.J.Sterling,
I.I.Tang,
S.G.Greenberg,
E.R.Williams,
and
B.A.Krantz
(2010).
Structural basis for the unfolding of anthrax lethal factor by protective antigen oligomers.
|
| |
Nat Struct Mol Biol, 17,
1383-1390.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
G.Wu,
C.Feng,
Y.Hong,
A.Guo,
S.Cao,
J.Dong,
L.Lin,
and
Z.Liu
(2010).
Soluble expression and purification of the anthrax protective antigen in E. coli and identification of a novel dominant-negative mutant N435C.
|
| |
Appl Microbiol Biotechnol, 87,
609-616.
|
|
|
|
|
|
|
H.Katayama,
J.Wang,
F.Tama,
L.Chollet,
E.P.Gogol,
R.J.Collier,
and
M.T.Fisher
(2010).
Three-dimensional structure of the anthrax toxin pore inserted into lipid nanodiscs and lipid vesicles.
|
| |
Proc Natl Acad Sci U S A, 107,
3453-3457.
|
|
|
|
|
|
|
J.Sun,
and
R.J.Collier
(2010).
Disulfide bonds in the ectodomain of anthrax toxin receptor 2 are required for the receptor-bound protective-antigen pore to function.
|
| |
PLoS One, 5,
e10553.
|
|
|
|
|
|
|
K.Goossens,
and
R.Willaert
(2010).
Flocculation protein structure and cell-cell adhesion mechanism in Saccharomyces cerevisiae.
|
| |
Biotechnol Lett, 32,
1571-1585.
|
|
|
|
|
|
|
M.Radjainia,
J.K.Hyun,
C.E.Leysath,
S.H.Leppla,
and
A.K.Mitra
(2010).
Anthrax toxin-neutralizing antibody reconfigures the protective antigen heptamer into a supercomplex.
|
| |
Proc Natl Acad Sci U S A, 107,
14070-14074.
|
|
|
|
|
|
|
M.Veelders,
S.Brückner,
D.Ott,
C.Unverzagt,
H.U.Mösch,
and
L.O.Essen
(2010).
Structural basis of flocculin-mediated social behavior in yeast.
|
| |
Proc Natl Acad Sci U S A, 107,
22511-22516.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
R.A.Brady,
A.Verma,
B.D.Meade,
and
D.L.Burns
(2010).
Analysis of antibody responses to protective antigen-based anthrax vaccines through use of competitive assays.
|
| |
Clin Vaccine Immunol, 17,
1390-1397.
|
|
|
|
|
|
|
S.C.Kondos,
T.Hatfaludi,
I.Voskoboinik,
J.A.Trapani,
R.H.Law,
J.C.Whisstock,
and
M.A.Dunstone
(2010).
The structure and function of mammalian membrane-attack complex/perforin-like proteins.
|
| |
Tissue Antigens, 76,
341-351.
|
|
|
|
|
|
|
W.A.Langley,
K.C.Bradley,
Z.N.Li,
M.E.Smith,
M.J.Schnell,
and
D.A.Steinhauer
(2010).
Induction of neutralizing antibody responses to anthrax protective antigen by using influenza virus vectors: implications for disparate immune system priming pathways.
|
| |
J Virol, 84,
8300-8307.
|
|
|
|
|
|
|
A.F.Kintzer,
K.L.Thoren,
H.J.Sterling,
K.C.Dong,
G.K.Feld,
I.I.Tang,
T.T.Zhang,
E.R.Williams,
J.M.Berger,
and
B.A.Krantz
(2009).
The protective antigen component of anthrax toxin forms functional octameric complexes.
|
| |
J Mol Biol, 392,
614-629.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
A.Finkelstein
(2009).
Proton-coupled protein transport through the anthrax toxin channel.
|
| |
Philos Trans R Soc Lond B Biol Sci, 364,
209-215.
|
|
|
|
|
|
|
A.M.deCathelineau,
and
G.M.Bokoch
(2009).
Inactivation of rho GTPases by statins attenuates anthrax lethal toxin activity.
|
| |
Infect Immun, 77,
348-359.
|
|
|
|
|
|
|
A.S.Williams,
S.Lovell,
A.Anbanandam,
R.El-Chami,
and
J.G.Bann
(2009).
Domain 4 of the anthrax protective antigen maintains structure and binding to the host receptor CMG2 at low pH.
|
| |
Protein Sci, 18,
2277-2286.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
C.D.Kelly-Cirino,
and
N.J.Mantis
(2009).
Neutralizing monoclonal antibodies directed against defined linear epitopes on domain 4 of anthrax protective antigen.
|
| |
Infect Immun, 77,
4859-4867.
|
|
|
|
|
|
|
C.E.Leysath,
A.F.Monzingo,
J.A.Maynard,
J.Barnett,
G.Georgiou,
B.L.Iverson,
and
J.D.Robertus
(2009).
Crystal structure of the engineered neutralizing antibody M18 complexed to domain 4 of the anthrax protective antigen.
|
| |
J Mol Biol, 387,
680-693.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
D.Dodd,
S.A.Kocherginskaya,
M.A.Spies,
K.E.Beery,
C.A.Abbas,
R.I.Mackie,
and
I.K.Cann
(2009).
Biochemical analysis of a beta-D-xylosidase and a bifunctional xylanase-ferulic acid esterase from a xylanolytic gene cluster in Prevotella ruminicola 23.
|
| |
J Bacteriol, 191,
3328-3338.
|
|
|
|
|
|
|
D.Reason,
J.Liberato,
J.Sun,
W.Keitel,
and
J.Zhou
(2009).
Frequency and domain specificity of toxin-neutralizing paratopes in the human antibody response to anthrax vaccine adsorbed.
|
| |
Infect Immun, 77,
2030-2035.
|
|
|
|
|
|
|
F.Vahedi,
M.Sankian,
and
M.Mahmoudi
(2009).
Functional expression of Bacillus anthracis protective antigen in E. coli.
|
| |
Appl Biochem Biotechnol, 157,
554-561.
|
|
|
|
|
|
|
G.Caron,
A.Nurisso,
and
G.Ermondi
(2009).
How to extend the use of grid-based interaction energy maps from chemistry to biotopics.
|
| |
ChemMedChem, 4,
29-36.
|
|
|
|
|
|
|
G.Vernier,
J.Wang,
L.D.Jennings,
J.Sun,
A.Fischer,
L.Song,
and
R.J.Collier
(2009).
Solubilization and characterization of the anthrax toxin pore in detergent micelles.
|
| |
Protein Sci, 18,
1882-1895.
|
|
|
|
|
|
|
H.Hu,
and
S.H.Leppla
(2009).
Anthrax toxin uptake by primary immune cells as determined with a lethal factor-beta-lactamase fusion protein.
|
| |
PLoS One, 4,
e7946.
|
|
|
|
|
|
|
J.N.Tournier,
R.G.Ulrich,
A.Quesnel-Hellmann,
M.Mohamadzadeh,
and
B.G.Stiles
(2009).
Anthrax, toxins and vaccines: a 125-year journey targeting Bacillus anthracis.
|
| |
Expert Rev Anti Infect Ther, 7,
219-236.
|
|
|
|
|
|
|
J.Oscherwitz,
F.Yu,
J.L.Jacobs,
T.H.Liu,
P.R.Johnson,
and
K.B.Cease
(2009).
Synthetic peptide vaccine targeting a cryptic neutralizing epitope in domain 2 of Bacillus anthracis protective antigen.
|
| |
Infect Immun, 77,
3380-3388.
|
|
|
|
|
|
|
J.W.Ezzell,
T.G.Abshire,
R.Panchal,
D.Chabot,
S.Bavari,
E.K.Leffel,
B.Purcell,
A.M.Friedlander,
and
W.J.Ribot
(2009).
Association of Bacillus anthracis capsule with lethal toxin during experimental infection.
|
| |
Infect Immun, 77,
749-755.
|
|
|
|
|
|
|
K.Gawlik,
S.A.Shiryaev,
W.Zhu,
K.Motamedchaboki,
R.Desjardins,
R.Day,
A.G.Remacle,
B.Stec,
and
A.Y.Strongin
(2009).
Autocatalytic activation of the furin zymogen requires removal of the emerging enzyme's N-terminus from the active site.
|
| |
PLoS ONE, 4,
e5031.
|
|
|
|
|
|
|
M.R.Popoff,
and
P.Bouvet
(2009).
Clostridial toxins.
|
| |
Future Microbiol, 4,
1021-1064.
|
|
|
|
|
|
|
M.X.Macrae,
S.Blake,
X.Jiang,
R.Capone,
D.J.Estes,
M.Mayer,
and
J.Yang
(2009).
A semi-synthetic ion channel platform for detection of phosphatase and protease activity.
|
| |
ACS Nano, 3,
3567-3580.
|
|
|
|
|
|
|
N.Abboud,
M.De Jesus,
A.Nakouzi,
R.J.Cordero,
M.Pujato,
A.Fiser,
J.Rivera,
and
A.Casadevall
(2009).
Identification of linear epitopes in Bacillus anthracis protective antigen bound by neutralizing antibodies.
|
| |
J Biol Chem, 284,
25077-25086.
|
|
|
|
|
|
|
R.J.Collier
(2009).
Membrane translocation by anthrax toxin.
|
| |
Mol Aspects Med, 30,
413-422.
|
|
|
|
|
|
|
S.Cao,
A.Guo,
Z.Liu,
Y.Tan,
G.Wu,
C.Zhang,
Y.Zhao,
and
H.Chen
(2009).
Investigation of new dominant-negative inhibitors of anthrax protective antigen mutants for use in therapy and vaccination.
|
| |
Infect Immun, 77,
4679-4687.
|
|
|
|
|
|
|
T.Liu,
and
R.B.Altman
(2009).
Prediction of calcium-binding sites by combining loop-modeling with machine learning.
|
| |
BMC Struct Biol, 9,
72.
|
|
|
|
|
|
|
Z.Chen,
M.Moayeri,
H.Zhao,
D.Crown,
S.H.Leppla,
and
R.H.Purcell
(2009).
Potent neutralization of anthrax edema toxin by a humanized monoclonal antibody that competes with calmodulin for edema factor binding.
|
| |
Proc Natl Acad Sci U S A, 106,
13487-13492.
|
|
|
|
|
|
|
A.Sivasubramanian,
J.A.Maynard,
and
J.J.Gray
(2008).
Modeling the structure of mAb 14B7 bound to the anthrax protective antigen.
|
| |
Proteins, 70,
218-230.
|
|
|
|
|
|
|
A.Valeva,
I.Siegel,
M.Wylenzek,
T.M.Wassenaar,
S.Weis,
N.Heinz,
R.Schmitt,
C.Fischer,
R.Reinartz,
S.Bhakdi,
and
I.Walev
(2008).
Putative identification of an amphipathic alpha-helical sequence in hemolysin of Escherichia coli (HlyA) involved in transmembrane pore formation.
|
| |
Biol Chem, 389,
1201-1207.
|
|
|
|
|
|
|
B.J.Nablo,
K.M.Halverson,
J.W.Robertson,
T.L.Nguyen,
R.G.Panchal,
R.Gussio,
S.Bavari,
O.V.Krasilnikov,
and
J.J.Kasianowicz
(2008).
Sizing the Bacillus anthracis PA63 channel with nonelectrolyte poly(ethylene glycols).
|
| |
Biophys J, 95,
1157-1164.
|
|
|
|
|
|
|
B.Zhou,
C.Carney,
and
K.D.Janda
(2008).
Selection and characterization of human antibodies neutralizing Bacillus anthracis toxin.
|
| |
Bioorg Med Chem, 16,
1903-1913.
|
|
|
|
|
|
|
D.C.Reason,
A.Ullal,
J.Liberato,
J.Sun,
W.Keitel,
and
J.Zhou
(2008).
Domain specificity of the human antibody response to Bacillus anthracis protective antigen.
|
| |
Vaccine, 26,
4041-4047.
|
|
|
|
|
|
|
D.S.Anderson,
and
R.O.Blaustein
(2008).
Preventing voltage-dependent gating of anthrax toxin channels using engineered disulfides.
|
| |
J Gen Physiol, 132,
351-360.
|
|
|
|
|
|
|
G.Anderluh,
and
J.H.Lakey
(2008).
Disparate proteins use similar architectures to damage membranes.
|
| |
Trends Biochem Sci, 33,
482-490.
|
|
|
|
|
|
|
H.Jang,
J.Zheng,
R.Lal,
and
R.Nussinov
(2008).
New structures help the modeling of toxic amyloidbeta ion channels.
|
| |
Trends Biochem Sci, 33,
91.
|
|
|
|
|
|
|
H.Katayama,
B.E.Janowiak,
M.Brzozowski,
J.Juryck,
S.Falke,
E.P.Gogol,
R.J.Collier,
and
M.T.Fisher
(2008).
GroEL as a molecular scaffold for structural analysis of the anthrax toxin pore.
|
| |
Nat Struct Mol Biol, 15,
754-760.
|
|
|
|
|
|
|
J.G.Smedley,
J.S.Sharp,
J.F.Kuhn,
and
K.B.Tomer
(2008).
Probing the pH-dependent prepore to pore transition of Bacillus anthracis protective antigen with differential oxidative protein footprinting.
|
| |
Biochemistry, 47,
10694-10704.
|
|
|
|
|
|
|
J.Sun,
A.E.Lang,
K.Aktories,
and
R.J.Collier
(2008).
Phenylalanine-427 of anthrax protective antigen functions in both pore formation and protein translocation.
|
| |
Proc Natl Acad Sci U S A, 105,
4346-4351.
|
|
|
|
|
|
|
J.Zhou,
A.Ullal,
J.Liberato,
J.Sun,
W.Keitel,
and
D.C.Reason
(2008).
Paratope diversity in the human antibody response to Bacillus anthracis protective antigen.
|
| |
Mol Immunol, 45,
338-347.
|
|
|
|
|
|
|
K.Shahidullah,
and
E.London
(2008).
Effect of lipid composition on the topography of membrane-associated hydrophobic helices: stabilization of transmembrane topography by anionic lipids.
|
| |
J Mol Biol, 379,
704-718.
|
|
|
|
|
|
|
M.L.Zupancic,
M.Frieman,
D.Smith,
R.A.Alvarez,
R.D.Cummings,
and
B.P.Cormack
(2008).
Glycan microarray analysis of Candida glabrata adhesin ligand specificity.
|
| |
Mol Microbiol, 68,
547-559.
|
|
|
|
|
|
|
M.Yan,
M.H.Roehrl,
E.Basar,
and
J.Y.Wang
(2008).
Selection and evaluation of the immunogenicity of protective antigen mutants as anthrax vaccine candidates.
|
| |
Vaccine, 26,
947-955.
|
|
|
|
|
|
|
N.Abboud,
and
A.Casadevall
(2008).
Immunogenicity of Bacillus anthracis protective antigen domains and efficacy of elicited antibody responses depend on host genetic background.
|
| |
Clin Vaccine Immunol, 15,
1115-1123.
|
|
|
|
|
|
|
S.C.Taft,
and
A.A.Weiss
(2008).
Toxicity of anthrax toxin is influenced by receptor expression.
|
| |
Clin Vaccine Immunol, 15,
1330-1336.
|
|
|
|
|
|
|
T.Neumeyer,
B.Schiffler,
E.Maier,
A.E.Lang,
K.Aktories,
and
R.Benz
(2008).
Clostridium botulinum C2 toxin. Identification of the binding site for chloroquine and related compounds and influence of the binding site on properties of the C2II channel.
|
| |
J Biol Chem, 283,
3904-3914.
|
|
|
|
|
|
|
B.S.Powell,
J.T.Enama,
W.J.Ribot,
W.Webster,
S.Little,
T.Hoover,
J.J.Adamovicz,
and
G.P.Andrews
(2007).
Multiple asparagine deamidation of Bacillus anthracis protective antigen causes charge isoforms whose complexity correlates with reduced biological activity.
|
| |
Proteins, 68,
458-479.
|
|
|
|
|
|
|
G.T.Vilas-Bôas,
A.P.Peruca,
and
O.M.Arantes
(2007).
Biology and taxonomy of Bacillus cereus, Bacillus anthracis, and Bacillus thuringiensis.
|
| |
Can J Microbiol, 53,
673-687.
|
|
|
|
|
|
|
J.A.Young,
and
R.J.Collier
(2007).
Anthrax toxin: receptor binding, internalization, pore formation, and translocation.
|
| |
Annu Rev Biochem, 76,
243-265.
|
|
|
|
|
|
|
J.J.Young,
J.L.Bromberg-White,
C.Zylstra,
J.T.Church,
E.Boguslawski,
J.H.Resau,
B.O.Williams,
and
N.S.Duesbery
(2007).
LRP5 and LRP6 are not required for protective antigen-mediated internalization or lethality of anthrax lethal toxin.
|
| |
PLoS Pathog, 3,
e27.
|
|
|
|
|
|
|
J.N.Tournier,
A.Quesnel-Hellmann,
A.Cleret,
and
D.R.Vidal
(2007).
Contribution of toxins to the pathogenesis of inhalational anthrax.
|
| |
Cell Microbiol, 9,
555-565.
|
|
|
|
|
|
|
J.Sun,
G.Vernier,
D.J.Wigelsworth,
and
R.J.Collier
(2007).
Insertion of anthrax protective antigen into liposomal membranes: effects of a receptor.
|
| |
J Biol Chem, 282,
1059-1065.
|
|
|
|
|
|
|
K.H.Chen,
S.Liu,
L.A.Bankston,
R.C.Liddington,
and
S.H.Leppla
(2007).
Selection of anthrax toxin protective antigen variants that discriminate between the cellular receptors TEM8 and CMG2 and achieve targeting of tumor cells.
|
| |
J Biol Chem, 282,
9834-9845.
|
|
|
|
|
|
|
K.Sherer,
Y.Li,
X.Cui,
and
P.Q.Eichacker
(2007).
Lethal and edema toxins in the pathogenesis of Bacillus anthracis septic shock: implications for therapy.
|
| |
Am J Respir Crit Care Med, 175,
211-221.
|
|
|
|
|
|
|
L.Xu,
and
D.M.Frucht
(2007).
Bacillus anthracis: a multi-faceted role for anthrax lethal toxin in thwarting host immune defenses.
|
| |
Int J Biochem Cell Biol, 39,
20-24.
|
|
|
|
|
|
|
M.J.McConnell,
P.C.Hanna,
and
M.J.Imperiale
(2007).
Adenovirus-based Prime-boost Immunization for Rapid Vaccination Against Anthrax.
|
| |
Mol Ther, 15,
203-210.
|
|
|
|
|
|
|
M.R.Baldwin,
J.J.Kim,
and
J.T.Barbieri
(2007).
Botulinum neurotoxin B-host receptor recognition: it takes two receptors to tango.
|
| |
Nat Struct Mol Biol, 14,
9.
|
|
|
|
|
|
|
M.Triantafilou,
A.Uddin,
S.Maher,
N.Charalambous,
T.S.Hamm,
A.Alsumaiti,
and
K.Triantafilou
(2007).
Anthrax toxin evades Toll-like receptor recognition, whereas its cell wall components trigger activation via TLR2/6 heterodimers.
|
| |
Cell Microbiol, 9,
2880-2892.
|
|
|
|
|
|
|
R.V.Kolla,
S.Chintalapati,
M.Sabet,
E.Santelli,
R.C.Liddington,
M.David,
J.Fierer,
D.Guiney,
and
R.C.Rickert
(2007).
Complement c3d conjugation to anthrax protective antigen promotes a rapid, sustained, and protective antibody response.
|
| |
PLoS ONE, 2,
e1044.
|
|
|
|
|
|
|
S.B.Shivachandra,
Q.Li,
K.K.Peachman,
G.R.Matyas,
S.H.Leppla,
C.R.Alving,
M.Rao,
and
V.B.Rao
(2007).
Multicomponent anthrax toxin display and delivery using bacteriophage T4.
|
| |
Vaccine, 25,
1225-1235.
|
|
|
|
|
|
|
S.J.Juris,
R.A.Melnyk,
R.E.Bolcome,
J.Chan,
and
R.J.Collier
(2007).
Cross-linked forms of the isolated N-terminal domain of the lethal factor are potent inhibitors of anthrax toxin.
|
| |
Infect Immun, 75,
5052-5058.
|
|
|
|
|
|
|
S.K.Das,
M.Darshi,
S.Cheley,
M.I.Wallace,
and
H.Bayley
(2007).
Membrane protein stoichiometry determined from the step-wise photobleaching of dye-labelled subunits.
|
| |
Chembiochem, 8,
994-999.
|
|
|
|
|
|
|
S.L.Johnson,
L.H.Chen,
and
M.Pellecchia
(2007).
A high-throughput screening approach to anthrax lethal factor inhibition.
|
| |
Bioorg Chem, 35,
306-312.
|
|
|
|
|
|
|
S.Liu,
H.J.Leung,
and
S.H.Leppla
(2007).
Characterization of the interaction between anthrax toxin and its cellular receptors.
|
| |
Cell Microbiol, 9,
977-987.
|
|
|
|
|
|
|
S.Meier,
and
S.Ozbek
(2007).
A biological cosmos of parallel universes: does protein structural plasticity facilitate evolution?
|
| |
Bioessays, 29,
1095-1104.
|
|
|
|
|
|
|
V.A.Karginov,
E.M.Nestorovich,
F.Schmidtmann,
T.M.Robinson,
A.Yohannes,
N.E.Fahmi,
S.M.Bezrukov,
and
S.M.Hecht
(2007).
Inhibition of S. aureus alpha-hemolysin and B. anthracis lethal toxin by beta-cyclodextrin derivatives.
|
| |
Bioorg Med Chem, 15,
5424-5431.
|
|
|
|
|
|
|
Y.Li,
K.Sherer,
X.Cui,
and
P.Q.Eichacker
(2007).
New insights into the pathogenesis and treatment of anthrax toxin-induced shock.
|
| |
Expert Opin Biol Ther, 7,
843-854.
|
|
|
|
|
|
|
A.Brik,
C.Y.Wu,
and
C.H.Wong
(2006).
Microtiter plate based chemistry and in situ screening: a useful approach for rapid inhibitor discovery.
|
| |
Org Biomol Chem, 4,
1446-1457.
|
|
|
|
|
|
|
A.E.Gerdon,
D.W.Wright,
and
D.E.Cliffel
(2006).
Epitope mapping of the protective antigen of B. anthracis by using nanoclusters presenting conformational peptide epitopes.
|
| |
Angew Chem Int Ed Engl, 45,
594-598.
|
|
|
|
|
|
|
F.Tama,
G.Ren,
C.L.Brooks,
and
A.K.Mitra
(2006).
Model of the toxic complex of anthrax: responsive conformational changes in both the lethal factor and the protective antigen heptamer.
|
| |
Protein Sci, 15,
2190-2200.
|
|
|
|
|
|
|
G.S.Jiao,
L.Cregar,
J.Wang,
S.Z.Millis,
C.Tang,
S.O'Malley,
A.T.Johnson,
S.Sareth,
J.Larson,
and
G.Thomas
(2006).
Synthetic small molecule furin inhibitors derived from 2,5-dideoxystreptamine.
|
| |
Proc Natl Acad Sci U S A, 103,
19707-19712.
|
|
|
|
|
|
|
J.F.Hanson,
S.C.Taft,
and
A.A.Weiss
(2006).
Neutralizing antibodies and persistence of immunity following anthrax vaccination.
|
| |
Clin Vaccine Immunol, 13,
208-213.
|
|
|
|
|
|
|
K.A.Christensen,
B.A.Krantz,
and
R.J.Collier
(2006).
Assembly and disassembly kinetics of anthrax toxin complexes.
|
| |
Biochemistry, 45,
2380-2386.
|
|
|
|
|
|
|
L.W.Baillie
(2006).
Past, imminent and future human medical countermeasures for anthrax.
|
| |
J Appl Microbiol, 101,
594-606.
|
|
|
|
|
|
|
M.E.Goldman,
L.Cregar,
D.Nguyen,
O.Simo,
S.O'Malley,
and
T.Humphreys
(2006).
Cationic polyamines inhibit anthrax lethal factor protease.
|
| |
BMC Pharmacol, 6,
8.
|
|
|
|
|
|
|
M.Gao,
and
K.Schulten
(2006).
Onset of anthrax toxin pore formation.
|
| |
Biophys J, 90,
3267-3279.
|
|
|
|
|
|
|
M.J.Gubbins,
J.D.Berry,
C.R.Corbett,
J.Mogridge,
X.Y.Yuan,
L.Schmidt,
B.Nicolas,
A.Kabani,
and
R.S.Tsang
(2006).
Production and characterization of neutralizing monoclonal antibodies that recognize an epitope in domain 2 of Bacillus anthracis protective antigen.
|
| |
FEMS Immunol Med Microbiol, 47,
436-443.
|
|
|
|
|
|
|
M.J.McConnell,
P.C.Hanna,
and
M.J.Imperiale
(2006).
Cytokine response and survival of mice immunized with an adenovirus expressing Bacillus anthracis protective antigen domain 4.
|
| |
Infect Immun, 74,
1009-1015.
|
|
|
|
|
|
|
R.A.Melnyk,
and
R.J.Collier
(2006).
A loop network within the anthrax toxin pore positions the phenylalanine clamp in an active conformation.
|
| |
Proc Natl Acad Sci U S A, 103,
9802-9807.
|
|
|
|
|
|
|
S.Heninger,
M.Drysdale,
J.Lovchik,
J.Hutt,
M.F.Lipscomb,
T.M.Koehler,
and
C.R.Lyons
(2006).
Toxin-deficient mutants of Bacillus anthracis are lethal in a murine model for pulmonary anthrax.
|
| |
Infect Immun, 74,
6067-6074.
|
|
|
|
|
|
|
S.J.Tilley,
and
H.R.Saibil
(2006).
The mechanism of pore formation by bacterial toxins.
|
| |
Curr Opin Struct Biol, 16,
230-236.
|
|
|
|
|
|
|
T.Neumeyer,
F.Tonello,
F.Dal Molin,
B.Schiffler,
and
R.Benz
(2006).
Anthrax edema factor, voltage-dependent binding to the protective antigen ion channel and comparison to LF binding.
|
| |
J Biol Chem, 281,
32335-32343.
|
|
|
|
|
|
|
V.A.Karginov,
E.M.Nestorovich,
A.Yohannes,
T.M.Robinson,
N.E.Fahmi,
F.Schmidtmann,
S.M.Hecht,
and
S.M.Bezrukov
(2006).
Search for cyclodextrin-based inhibitors of anthrax toxins: synthesis, structural features, and relative activities.
|
| |
Antimicrob Agents Chemother, 50,
3740-3753.
|
|
|
|
|
|
|
W.A.Keitel
(2006).
Recombinant protective antigen 102 (rPA102): profile of a second-generation anthrax vaccine.
|
| |
Expert Rev Vaccines, 5,
417-430.
|
|
|
|
|
|
|
Y.Zhou,
W.Yang,
M.Kirberger,
H.W.Lee,
G.Ayalasomayajula,
and
J.J.Yang
(2006).
Prediction of EF-hand calcium-binding proteins and analysis of bacterial EF-hand proteins.
|
| |
Proteins, 65,
643-655.
|
|
|
|
|
|
|
B.A.Aulinger,
M.H.Roehrl,
J.J.Mekalanos,
R.J.Collier,
and
J.Y.Wang
(2005).
Combining anthrax vaccine and therapy: a dominant-negative inhibitor of anthrax toxin is also a potent and safe immunogen for vaccines.
|
| |
Infect Immun, 73,
3408-3414.
|
|
|
|
|
|
|
B.Promdonkoy,
and
D.J.Ellar
(2005).
Structure-function relationships of a membrane pore forming toxin revealed by reversion mutagenesis.
|
| |
Mol Membr Biol, 22,
327-337.
|
|
|
|
|
|
|
C.C.Hu,
F.X.Liang,
G.Zhou,
L.Tu,
C.H.Tang,
J.Zhou,
G.Kreibich,
and
T.T.Sun
(2005).
Assembly of urothelial plaques: tetraspanin function in membrane protein trafficking.
|
| |
Mol Biol Cell, 16,
3937-3950.
|
|
|
|
|
|
|
D.V.Rozanov,
V.S.Golubkov,
and
A.Y.Strongin
(2005).
Membrane type-1 matrix metalloproteinase (MT1-MMP) protects malignant cells from tumoricidal activity of re-engineered anthrax lethal toxin.
|
| |
Int J Biochem Cell Biol, 37,
142-154.
|
|
|
|
|
|
|
E.D.Williamson,
I.Hodgson,
N.J.Walker,
A.W.Topping,
M.G.Duchars,
J.M.Mott,
J.Estep,
C.Lebutt,
H.C.Flick-Smith,
H.E.Jones,
H.Li,
and
C.P.Quinn
(2005).
Immunogenicity of recombinant protective antigen and efficacy against aerosol challenge with anthrax.
|
| |
Infect Immun, 73,
5978-5987.
|
|
|
|
|
|
|
E.Laffly,
L.Danjou,
F.Condemine,
D.Vidal,
E.Drouet,
M.P.Lefranc,
C.Bottex,
and
P.Thullier
(2005).
Selection of a macaque Fab with framework regions like those in humans, high affinity, and ability to neutralize the protective antigen (PA) of Bacillus anthracis by binding to the segment of PA between residues 686 and 694.
|
| |
Antimicrob Agents Chemother, 49,
3414-3420.
|
|
|
|
|
|
|
F.Orlik,
B.Schiffler,
and
R.Benz
(2005).
Anthrax toxin protective antigen: inhibition of channel function by chloroquine and related compounds and study of binding kinetics using the current noise analysis.
|
| |
Biophys J, 88,
1715-1724.
|
|
|
|
|
|
|
G.E.Rhie,
Y.M.Park,
J.H.Chun,
C.K.Yoo,
W.K.Seong,
and
H.B.Oh
(2005).
Expression and secretion of the protective antigen of Bacillus anthracis in Bacillus brevis.
|
| |
FEMS Immunol Med Microbiol, 45,
331-339.
|
|
|
|
|
|
|
G.E.Rhie,
Y.M.Park,
J.S.Han,
J.Y.Yu,
W.K.Seong,
and
H.B.Oh
(2005).
Efficacy of non-toxic deletion mutants of protective antigen from Bacillus anthracis.
|
| |
FEMS Immunol Med Microbiol, 45,
341-347.
|
|
|
|
|
|
|
G.J.Rainey,
D.J.Wigelsworth,
P.L.Ryan,
H.M.Scobie,
R.J.Collier,
and
J.A.Young
(2005).
Receptor-specific requirements for anthrax toxin delivery into cells.
|
| |
Proc Natl Acad Sci U S A, 102,
13278-13283.
|
|
|
|
|
|
|
G.Zomber,
S.Reuveny,
N.Garti,
A.Shafferman,
and
E.Elhanany
(2005).
Effects of spontaneous deamidation on the cytotoxic activity of the Bacillus anthracis protective antigen.
|
| |
J Biol Chem, 280,
39897-39906.
|
|
|
|
|
|
|
J.T.Wolfe,
B.A.Krantz,
G.J.Rainey,
J.A.Young,
and
R.J.Collier
(2005).
Whole-cell voltage clamp measurements of anthrax toxin pore current.
|
| |
J Biol Chem, 280,
39417-39422.
|
|
|
|
|
|
|
J.Y.Wang,
and
M.H.Roehrl
(2005).
Anthrax vaccine design: strategies to achieve comprehensive protection against spore, bacillus, and toxin.
|
| |
Med Immunol, 4,
4.
|
|
|
|
|
|
|
K.M.Halverson,
R.G.Panchal,
T.L.Nguyen,
R.Gussio,
S.F.Little,
M.Misakian,
S.Bavari,
and
J.J.Kasianowicz
(2005).
Anthrax biosensor, protective antigen ion channel asymmetric blockade.
|
| |
J Biol Chem, 280,
34056-34062.
|
|
|
|
|
|
|
L.Abrami,
N.Reig,
and
F.G.van der Goot
(2005).
Anthrax toxin: the long and winding road that leads to the kill.
|
| |
Trends Microbiol, 13,
72-78.
|
|
|
|
|
|
|
M.Forino,
S.Johnson,
T.Y.Wong,
D.V.Rozanov,
A.Y.Savinov,
W.Li,
R.Fattorusso,
B.Becattini,
A.J.Orry,
D.Jung,
R.A.Abagyan,
J.W.Smith,
K.Alibek,
R.C.Liddington,
A.Y.Strongin,
and
M.Pellecchia
(2005).
Efficient synthetic inhibitors of anthrax lethal factor.
|
| |
Proc Natl Acad Sci U S A, 102,
9499-9504.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
M.M.Numa,
L.V.Lee,
C.C.Hsu,
K.E.Bower,
and
C.H.Wong
(2005).
Identification of novel anthrax lethal factor inhibitors generated by combinatorial Pictet-Spengler reaction followed by screening in situ.
|
| |
Chembiochem, 6,
1002-1006.
|
|
|
|
|
|
|
M.Qa'dan,
K.A.Christensen,
L.Zhang,
T.M.Roberts,
and
R.J.Collier
(2005).
Membrane insertion by anthrax protective antigen in cultured cells.
|
| |
Mol Cell Biol, 25,
5492-5498.
|
|
|
|
|
|
|
N.Mohamed,
M.Clagett,
J.Li,
S.Jones,
S.Pincus,
G.D'Alia,
L.Nardone,
M.Babin,
G.Spitalny,
and
L.Casey
(2005).
A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge.
|
| |
Infect Immun, 73,
795-802.
|
|
|
|
|
|
|
R.J.Gilbert
(2005).
Inactivation and activity of cholesterol-dependent cytolysins: what structural studies tell us.
|
| |
Structure, 13,
1097-1106.
|
|
|
|
|
|
|
R.N.Brey
(2005).
Molecular basis for improved anthrax vaccines.
|
| |
Adv Drug Deliv Rev, 57,
1266-1292.
|
|
|
|
|
|
|
R.Ramachandran,
R.K.Tweten,
and
A.E.Johnson
(2005).
The domains of a cholesterol-dependent cytolysin undergo a major FRET-detected rearrangement during pore formation.
|
| |
Proc Natl Acad Sci U S A, 102,
7139-7144.
|
|
|
|
|
|
|
S.D.Perkins,
H.C.Flick-Smith,
H.S.Garmory,
A.E.Essex-Lopresti,
F.K.Stevenson,
and
R.J.Phillpotts
(2005).
Evaluation of the VP22 protein for enhancement of a DNA vaccine against anthrax.
|
| |
Genet Vaccines Ther, 3,
3.
|
|
|
|
|
|
|
S.F.Little
(2005).
Anthrax vaccines: a development update.
|
| |
BioDrugs, 19,
233-245.
|
|
|
|
|
|
|
S.Liu,
V.Redeye,
J.G.Kuremsky,
M.Kuhnen,
A.Molinolo,
T.H.Bugge,
and
S.H.Leppla
(2005).
Intermolecular complementation achieves high-specificity tumor targeting by anthrax toxin.
|
| |
Nat Biotechnol, 23,
725-730.
|
|
|
|
|
|
|
T.Komiyama,
J.A.Swanson,
and
R.S.Fuller
(2005).
Protection from anthrax toxin-mediated killing of macrophages by the combined effects of furin inhibitors and chloroquine.
|
| |
Antimicrob Agents Chemother, 49,
3875-3882.
|
|
|
|
|
|
|
V.A.Karginov,
E.M.Nestorovich,
M.Moayeri,
S.H.Leppla,
and
S.M.Bezrukov
(2005).
Blocking anthrax lethal toxin at the protective antigen channel by using structure-inspired drug design.
|
| |
Proc Natl Acad Sci U S A, 102,
15075-15080.
|
|
|
|
|
|
|
Z.N.Li,
S.N.Mueller,
L.Ye,
Z.Bu,
C.Yang,
R.Ahmed,
and
D.A.Steinhauer
(2005).
Chimeric influenza virus hemagglutinin proteins containing large domains of the Bacillus anthracis protective antigen: protein characterization, incorporation into infectious influenza viruses, and antigenicity.
|
| |
J Virol, 79,
10003-10012.
|
|
|
|
|
|
|
B.L.Kagan,
R.Azimov,
and
R.Azimova
(2004).
Amyloid peptide channels.
|
| |
J Membr Biol, 202,
1.
|
|
|
|
|
|
|
D.B.Lacy,
D.J.Wigelsworth,
R.A.Melnyk,
S.C.Harrison,
and
R.J.Collier
(2004).
Structure of heptameric protective antigen bound to an anthrax toxin receptor: a role for receptor in pH-dependent pore formation.
|
| |
Proc Natl Acad Sci U S A, 101,
13147-13151.
|
|
|
PDB codes:
|
|
|
|
|
|
|
|
D.J.Rigden,
L.V.Mello,
and
M.Y.Galperin
(2004).
The PA14 domain, a conserved all-beta domain in bacterial toxins, enzymes, adhesins and signaling molecules.
|
| |
Trends Biochem Sci, 29,
335-339.
|
|
|
|
|
|
|
D.J.Wigelsworth,
B.A.Krantz,
K.A.Christensen,
D.B.Lacy,
S.J.Juris,
and
R.J.Collier
(2004).
Binding stoichiometry and kinetics of the interaction of a human anthrax toxin receptor, CMG2, with protective antigen.
|
| |
J Biol Chem, 279,
23349-23356.
|
|
|
|
|
|
|
D.M.Czajkowsky,
E.M.Hotze,
Z.Shao,
and
R.K.Tweten
(2004).
Vertical collapse of a cytolysin prepore moves its transmembrane beta-hairpins to the membrane.
|
| |
EMBO J, 23,
3206-3215.
|
|
|
|
|
|
|
E.Santelli,
L.A.Bankston,
S.H.Leppla,
and
R.C.Liddington
(2004).
Crystal structure of a complex between anthrax toxin and its host cell receptor.
|
| |
Nature, 430,
905-908.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
H.Barth,
K.Aktories,
M.R.Popoff,
and
B.G.Stiles
(2004).
Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins.
|
| |
Microbiol Mol Biol Rev, 68,
373.
|
|
|
|
|
|
|
J.E.Galen,
L.Zhao,
M.Chinchilla,
J.Y.Wang,
M.F.Pasetti,
J.Green,
and
M.M.Levine
(2004).
Adaptation of the endogenous Salmonella enterica serovar Typhi clyA-encoded hemolysin for antigen export enhances the immunogenicity of anthrax protective antigen domain 4 expressed by the attenuated live-vector vaccine strain CVD 908-htrA.
|
| |
Infect Immun, 72,
7096-7106.
|
|
|
|
|
|
|
J.G.Bann,
and
S.J.Hultgren
(2004).
Structural biology: anthrax hijacks host receptor.
|
| |
Nature, 430,
843-844.
|
|
|
|
|
|
|
M.Nagahama,
A.Yamaguchi,
T.Hagiyama,
N.Ohkubo,
K.Kobayashi,
and
J.Sakurai
(2004).
Binding and internalization of Clostridium perfringens iota-toxin in lipid rafts.
|
| |
Infect Immun, 72,
3267-3275.
|
|
|
|
|
|
|
M.S.Sarac,
J.R.Peinado,
S.H.Leppla,
and
I.Lindberg
(2004).
Protection against anthrax toxemia by hexa-D-arginine in vitro and in vivo.
|
| |
Infect Immun, 72,
602-605.
|
|
|
|
|
|
|
N.Mohamed,
J.Li,
C.S.Ferreira,
S.F.Little,
A.M.Friedlander,
G.L.Spitalny,
and
L.S.Casey
(2004).
Enhancement of anthrax lethal toxin cytotoxicity: a subset of monoclonal antibodies against protective antigen increases lethal toxin-mediated killing of murine macrophages.
|
| |
Infect Immun, 72,
3276-3283.
|
|
|
|
|
|
|
S.Galdiero,
and
E.Gouaux
(2004).
High resolution crystallographic studies of alpha-hemolysin-phospholipid complexes define heptamer-lipid head group interactions: implication for understanding protein-lipid interactions.
|
| |
Protein Sci, 13,
1503-1511.
|
|
|
|
|
|
|
S.Zhang,
A.Finkelstein,
and
R.J.Collier
(2004).
Evidence that translocation of anthrax toxin's lethal factor is initiated by entry of its N terminus into the protective antigen channel.
|
| |
Proc Natl Acad Sci U S A, 101,
16756-16761.
|
|
|
|
|
|
|
S.Zhang,
E.Udho,
Z.Wu,
R.J.Collier,
and
A.Finkelstein
(2004).
Protein translocation through anthrax toxin channels formed in planar lipid bilayers.
|
| |
Biophys J, 87,
3842-3849.
|
|
|
|
|
|
|
T.Uchida,
T.Yamasaki,
S.Eto,
H.Sugawara,
G.Kurisu,
A.Nakagawa,
M.Kusunoki,
and
T.Hatakeyama
(2004).
Crystal structure of the hemolytic lectin CEL-III isolated from the marine invertebrate Cucumaria echinata: implications of domain structure for its membrane pore-formation mechanism.
|
| |
J Biol Chem, 279,
37133-37141.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
X.Liang,
J.J.Young,
S.A.Boone,
D.S.Waugh,
and
N.S.Duesbery
(2004).
Involvement of domain II in toxicity of anthrax lethal factor.
|
| |
J Biol Chem, 279,
52473-52478.
|
|
|
|
|
|
|
Y.Shen,
N.L.Zhukovskaya,
M.I.Zimmer,
S.Soelaiman,
P.Bergson,
C.R.Wang,
C.S.Gibbs,
and
W.J.Tang
(2004).
Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.
|
| |
Proc Natl Acad Sci U S A, 101,
3242-3247.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
A.Agrawal,
J.Lingappa,
S.H.Leppla,
S.Agrawal,
A.Jabbar,
C.Quinn,
and
B.Pulendran
(2003).
Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin.
|
| |
Nature, 424,
329-334.
|
|
|
|
|
|
|
A.S.Prince
(2003).
The host response to anthrax lethal toxin: unexpected observations.
|
| |
J Clin Invest, 112,
656-658.
|
|
|
|
|
|
|
C.J.Ackley,
M.R.Greene,
and
C.H.Lowrey
(2003).
Defensive applications of gene transfer technology in the face of bioterrorism: DNA-based vaccines and immune targeting.
|
| |
Expert Opin Biol Ther, 3,
1279-1289.
|
|
|
|
|
|
|
D.J.Rigden,
M.J.Jedrzejas,
and
M.Y.Galperin
(2003).
An extracellular calcium-binding domain in bacteria with a distant relationship to EF-hands.
|
| |
FEMS Microbiol Lett, 221,
103-110.
|
|
|
|
|
|
|
D.J.Rigden,
M.J.Jedrzejas,
O.V.Moroz,
and
M.Y.Galperin
(2003).
Structural diversity of calcium-binding proteins in bacteria: single-handed EF-hands?
|
| |
Trends Microbiol, 11,
295-297.
|
|
|
|
|
|
|
G.Haug,
C.Wilde,
J.Leemhuis,
D.K.Meyer,
K.Aktories,
and
H.Barth
(2003).
Cellular uptake of Clostridium botulinum C2 toxin: membrane translocation of a fusion toxin requires unfolding of its dihydrofolate reductase domain.
|
| |
Biochemistry, 42,
15284-15291.
|
|
|
|
|
|
|
H.M.Scobie,
G.J.Rainey,
K.A.Bradley,
and
J.A.Young
(2003).
Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor.
|
| |
Proc Natl Acad Sci U S A, 100,
5170-5174.
|
|
|
|
|
|
|
J.A.Musson,
N.Walker,
H.Flick-Smith,
E.D.Williamson,
and
J.H.Robinson
(2003).
Differential processing of CD4 T-cell epitopes from the protective antigen of Bacillus anthracis.
|
| |
J Biol Chem, 278,
52425-52431.
|
|
|
|
|
|
|
J.S.Lee,
A.G.Hadjipanayis,
and
S.L.Welkos
(2003).
Venezuelan equine encephalitis virus-vectored vaccines protect mice against anthrax spore challenge.
|
| |
Infect Immun, 71,
1491-1496.
|
|
|
|
|
|
|
K.A.Bradley,
J.Mogridge,
G.Jonah,
A.Rainey,
S.Batty,
and
J.A.Young
(2003).
Binding of anthrax toxin to its receptor is similar to alpha integrin-ligand interactions.
|
| |
J Biol Chem, 278,
49342-49347.
|
|
|
|
|
|
|
L.Abrami,
S.Liu,
P.Cosson,
S.H.Leppla,
and
F.G.van der Goot
(2003).
Anthrax toxin triggers endocytosis of its receptor via a lipid raft-mediated clathrin-dependent process.
|
| |
J Cell Biol, 160,
321-328.
|
|
|
|
|
|
|
M.A.Palladino,
F.R.Bahjat,
E.A.Theodorakis,
and
L.L.Moldawer
(2003).
Anti-TNF-alpha therapies: the next generation.
|
| |
Nat Rev Drug Discov, 2,
736-746.
|
|
|
|
|
|
|
M.J.Rosovitz,
P.Schuck,
M.Varughese,
A.P.Chopra,
V.Mehra,
Y.Singh,
L.M.McGinnis,
and
S.H.Leppla
(2003).
Alanine-scanning mutations in domain 4 of anthrax toxin protective antigen reveal residues important for binding to the cellular receptor and to a neutralizing monoclonal antibody.
|
| |
J Biol Chem, 278,
30936-30944.
|
|
|
|
|
|
|
M.Mourez,
M.Yan,
D.B.Lacy,
L.Dillon,
L.Bentsen,
A.Marpoe,
C.Maurin,
E.Hotze,
D.Wigelsworth,
R.A.Pimental,
J.D.Ballard,
R.J.Collier,
and
R.K.Tweten
(2003).
Mapping dominant-negative mutations of anthrax protective antigen by scanning mutagenesis.
|
| |
Proc Natl Acad Sci U S A, 100,
13803-13808.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
M.Yan,
and
R.J.Collier
(2003).
Characterization of dominant-negative forms of anthrax protective antigen.
|
| |
Mol Med, 9,
46-51.
|
|
|
|
|
|
|
P.Malovrh,
G.Viero,
M.D.Serra,
Z.Podlesek,
J.H.Lakey,
P.Macek,
G.Menestrina,
and
G.Anderluh
(2003).
A novel mechanism of pore formation: membrane penetration by the N-terminal amphipathic region of equinatoxin.
|
| |
J Biol Chem, 278,
22678-22685.
|
|
|
|
|
|
|
R.A.de Maagd,
A.Bravo,
C.Berry,
N.Crickmore,
and
H.E.Schnepf
(2003).
Structure, diversity, and evolution of protein toxins from spore-forming entomopathogenic bacteria.
|
| |
Annu Rev Genet, 37,
409-433.
|
|
|
|
|
|
|
R.J.Collier,
and
J.A.Young
(2003).
Anthrax toxin.
|
| |
Annu Rev Cell Dev Biol, 19,
45-70.
|
|
|
|
|
|
|
S.Liu,
R.L.Schubert,
T.H.Bugge,
and
S.H.Leppla
(2003).
Anthrax toxin: structures, functions and tumour targeting.
|
| |
Expert Opin Biol Ther, 3,
843-853.
|
|
|
|
|
|
|
S.Liu,
and
S.H.Leppla
(2003).
Cell surface tumor endothelium marker 8 cytoplasmic tail-independent anthrax toxin binding, proteolytic processing, oligomer formation, and internalization.
|
| |
J Biol Chem, 278,
5227-5234.
|
|
|
|
|
|
|
S.Soelaiman,
B.Q.Wei,
P.Bergson,
Y.S.Lee,
Y.Shen,
M.Mrksich,
B.K.Shoichet,
and
W.J.Tang
(2003).
Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough.
|
| |
J Biol Chem, 278,
25990-25997.
|
|
|
|
|
|
|
T.Kurzchalia
(2003).
Anthrax toxin rafts into cells.
|
| |
J Cell Biol, 160,
295-296.
|
|
|
|
|
|
|
E.K.Davies,
M.Glick,
K.N.Harrison,
and
W.G.Richards
(2002).
Pattern recognition and massively distributed computing.
|
| |
J Comput Chem, 23,
1544-1550.
|
|
|
|
|
|
|
E.M.Hotze,
A.P.Heuck,
D.M.Czajkowsky,
Z.Shao,
A.E.Johnson,
and
R.K.Tweten
(2002).
Monomer-monomer interactions drive the prepore to pore conversion of a beta-barrel-forming cholesterol-dependent cytolysin.
|
| |
J Biol Chem, 277,
11597-11605.
|
|
|
|
|
|
|
H.C.Flick-Smith,
J.E.Eyles,
R.Hebdon,
E.L.Waters,
R.J.Beedham,
T.J.Stagg,
J.Miller,
H.O.Alpar,
L.W.Baillie,
and
E.D.Williamson
(2002).
Mucosal or parenteral administration of microsphere-associated Bacillus anthracis protective antigen protects against anthrax infection in mice.
|
| |
Infect Immun, 70,
2022-2028.
|
|
|
|
|
|
|
H.C.Flick-Smith,
N.J.Walker,
P.Gibson,
H.Bullifent,
S.Hayward,
J.Miller,
R.W.Titball,
and
E.D.Williamson
(2002).
A recombinant carboxy-terminal domain of the protective antigen of Bacillus anthracis protects mice against anthrax infection.
|
| |
Infect Immun, 70,
1653-1656.
|
|
|
|
|
|
|
J.C.Marvaud,
B.G.Stiles,
A.Chenal,
D.Gillet,
M.Gibert,
L.A.Smith,
and
M.R.Popoff
(2002).
Clostridium perfringens iota toxin. Mapping of the Ia domain involved in docking with Ib and cellular internalization.
|
| |
J Biol Chem, 277,
43659-43666.
|
|
|
|
|
|
|
J.E.Thwaite,
L.W.Baillie,
N.M.Carter,
K.Stephenson,
M.Rees,
C.R.Harwood,
and
P.T.Emmerson
(2002).
Optimization of the cell wall microenvironment allows increased production of recombinant Bacillus anthracis protective antigen from B. subtilis.
|
| |
Appl Environ Microbiol, 68,
227-234.
|
|
|
|
|
|
|
J.Mogridge,
K.Cunningham,
D.B.Lacy,
M.Mourez,
and
R.J.Collier
(2002).
The lethal and edema factors of anthrax toxin bind only to oligomeric forms of the protective antigen.
|
| |
Proc Natl Acad Sci U S A, 99,
7045-7048.
|
|
|
|
|
|
|
K.Cunningham,
D.B.Lacy,
J.Mogridge,
and
R.J.Collier
(2002).
Mapping the lethal factor and edema factor binding sites on oligomeric anthrax protective antigen.
|
| |
Proc Natl Acad Sci U S A, 99,
7049-7053.
|
|
|
|
|
|
|
M.Mourez,
D.B.Lacy,
K.Cunningham,
R.Legmann,
B.R.Sellman,
J.Mogridge,
and
R.J.Collier
(2002).
2001: a year of major advances in anthrax toxin research.
|
| |
Trends Microbiol, 10,
287-293.
|
|
|
|
|
|
|
M.Nagahama,
K.Nagayasu,
K.Kobayashi,
and
J.Sakurai
(2002).
Binding component of Clostridium perfringens iota-toxin induces endocytosis in Vero cells.
|
| |
Infect Immun, 70,
1909-1914.
|
|
|
|
|
|
|
M.T.Stubbs
(2002).
Anthrax X-rayed: new opportunities for biodefence.
|
| |
Trends Pharmacol Sci, 23,
539-541.
|
|
|
|
|
|
|
N.Ariel,
A.Zvi,
H.Grosfeld,
O.Gat,
Y.Inbar,
B.Velan,
S.Cohen,
and
A.Shafferman
(2002).
Search for potential vaccine candidate open reading frames in the Bacillus anthracis virulence plasmid pXO1: in silico and in vitro screening.
|
| |
Infect Immun, 70,
6817-6827.
|
|
|
|
|
|
|
O.Knapp,
R.Benz,
M.Gibert,
J.C.Marvaud,
and
M.R.Popoff
(2002).
Interaction of Clostridium perfringens iota-toxin with lipid bilayer membranes. Demonstration of channel formation by the activated binding component Ib and channel block by the enzyme component Ia.
|
| |
J Biol Chem, 277,
6143-6152.
|
|
|
|
|
|
|
S.Nassi,
R.J.Collier,
and
A.Finkelstein
(2002).
PA63 channel of anthrax toxin: an extended beta-barrel.
|
| |
Biochemistry, 41,
1445-1450.
|
|
|
|
|
|
|
V.Chauhan,
and
R.Bhatnagar
(2002).
Identification of amino acid residues of anthrax protective antigen involved in binding with lethal factor.
|
| |
Infect Immun, 70,
4477-4484.
|
|
|
|
|
|
|
W.G.Richards
(2002).
Virtual screening using grid computing: the screensaver project.
|
| |
Nat Rev Drug Discov, 1,
551-555.
|
|
|
|
|
|
|
Y.Hirakura,
I.Carreras,
J.D.Sipe,
and
B.L.Kagan
(2002).
Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense.
|
| |
Amyloid, 9,
13-23.
|
|
|
|
|
|
|
A.Athanasiadis,
G.Anderluh,
P.Macek,
and
D.Turk
(2001).
Crystal structure of the soluble form of equinatoxin II, a pore-forming toxin from the sea anemone Actinia equina.
|
| |
Structure, 9,
341-346.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
A.P.Heuck,
R.K.Tweten,
and
A.E.Johnson
(2001).
Beta-barrel pore-forming toxins: intriguing dimorphic proteins.
|
| |
Biochemistry, 40,
9065-9073.
|
|
|
|
|
|
|
B.R.Sellman,
M.Mourez,
and
R.J.Collier
(2001).
Dominant-negative mutants of a toxin subunit: an approach to therapy of anthrax.
|
| |
Science, 292,
695-697.
|
|
|
|
|
|
|
C.Montecucco
(2001).
Detoxification of a bacterial toxin by the toxin itself.
|
| |
Trends Pharmacol Sci, 22,
493-494.
|
|
|
|
|
|
|
H.Khanna,
A.P.Chopra,
N.Arora,
A.Chaudhry,
and
Y.Singh
(2001).
Role of residues constituting the 2beta1 strand of domain II in the biological activity of anthrax protective antigen.
|
| |
FEMS Microbiol Lett, 199,
27-31.
|
|
|
|
|
|
|
H.Khanna,
P.K.Gupta,
A.Singh,
R.Chandra,
and
Y.Singh
(2001).
Participation of residue F552 in domain III of the protective antigen in the biological activity of anthrax lethal toxin.
|
| |
Biol Chem, 382,
941-946.
|
|
|
|
|
|
|
J.C.Marvaud,
T.Smith,
M.L.Hale,
M.R.Popoff,
L.A.Smith,
and
B.G.Stiles
(2001).
Clostridium perfringens iota-toxin: mapping of receptor binding and Ia docking domains on Ib.
|
| |
Infect Immun, 69,
2435-2441.
|
|
|
|
|
|
|
J.Mogridge,
M.Mourez,
and
R.J.Collier
(2001).
Involvement of domain 3 in oligomerization by the protective antigen moiety of anthrax toxin.
|
| |
J Bacteriol, 183,
2111-2116.
|
|
|
|
|
|
|
J.W.Watters,
K.Dewar,
J.Lehoczky,
V.Boyartchuk,
and
W.F.Dietrich
(2001).
Kif1C, a kinesin-like motor protein, mediates mouse macrophage resistance to anthrax lethal factor.
|
| |
Curr Biol, 11,
1503-1511.
|
|
|
|
|
|
|
L.Baillie
(2001).
The development of new vaccines against Bacillus anthracis.
|
| |
J Appl Microbiol, 91,
609-613.
|
|
|
|
|
|
|
M.J.Jedrzejas
(2001).
Pneumococcal virulence factors: structure and function.
|
| |
Microbiol Mol Biol Rev, 65,
187.
|
|
|
|
|
|
|
M.Mock,
and
A.Fouet
(2001).
Anthrax.
|
| |
Annu Rev Microbiol, 55,
647-671.
|
|
|
|
|
|
|
P.C.Hanna
(2001).
Anthrax: a motor protein determines anthrax susceptibility.
|
| |
Curr Biol, 11,
R905-R906.
|
|
|
|
|
|
|
Y.Hirakura,
and
B.L.Kagan
(2001).
Pore formation by beta-2-microglobulin: a mechanism for the pathogenesis of dialysis associated amyloidosis.
|
| |
Amyloid, 8,
94.
|
|
|
|
|
|
|
A.P.Heuck,
E.M.Hotze,
R.K.Tweten,
and
A.E.Johnson
(2000).
Mechanism of membrane insertion of a multimeric beta-barrel protein: perfringolysin O creates a pore using ordered and coupled conformational changes.
|
| |
Mol Cell, 6,
1233-1242.
|
|
|
|
|
|
|
D.Blöcker,
H.Barth,
E.Maier,
R.Benz,
J.T.Barbieri,
and
K.Aktories
(2000).
The C terminus of component C2II of Clostridium botulinum C2 toxin is essential for receptor binding.
|
| |
Infect Immun, 68,
4566-4573.
|
|
|
|
|
|
|
F.Brossier,
M.Weber-Levy,
M.Mock,
and
J.C.Sirard
(2000).
Role of toxin functional domains in anthrax pathogenesis.
|
| |
Infect Immun, 68,
1781-1786.
|
|
|
|
|
|
|
L.A.Shepard,
O.Shatursky,
A.E.Johnson,
and
R.K.Tweten
(2000).
The mechanism of pore assembly for a cholesterol-dependent cytolysin: formation of a large prepore complex precedes the insertion of the transmembrane beta-hairpins.
|
| |
Biochemistry, 39,
10284-10293.
|
|
|
|
|
|
|
L.Bernardi,
G.Vitale,
C.Montecucco,
and
A.Musacchio
(2000).
Expression, crystallization and preliminary X-ray diffraction studies of recombinant Bacillus anthracis lethal factor.
|
| |
Acta Crystallogr D Biol Crystallogr, 56,
1449-1451.
|
|
|
|
|
|
|
L.Q.Gu,
M.Dalla Serra,
J.B.Vincent,
G.Vigh,
S.Cheley,
O.Braha,
and
H.Bayley
(2000).
Reversal of charge selectivity in transmembrane protein pores by using noncovalent molecular adapters.
|
| |
Proc Natl Acad Sci U S A, 97,
3959-3964.
|
|
|
|
|
|
|
M.Gibert,
L.Petit,
S.Raffestin,
A.Okabe,
and
M.R.Popoff
(2000).
Clostridium perfringens iota-toxin requires activation of both binding and enzymatic components for cytopathic activity.
|
| |
Infect Immun, 68,
3848-3853.
|
|
|
|
|
|
|
R.Koebnik,
K.P.Locher,
and
P.Van Gelder
(2000).
Structure and function of bacterial outer membrane proteins: barrels in a nutshell.
|
| |
Mol Microbiol, 37,
239-253.
|
|
|
|
|
|
|
Y.Lu,
R.Friedman,
N.Kushner,
A.Doling,
L.Thomas,
N.Touzjian,
M.Starnbach,
and
J.Lieberman
(2000).
Genetically modified anthrax lethal toxin safely delivers whole HIV protein antigens into the cytosol to induce T cell immunity.
|
| |
Proc Natl Acad Sci U S A, 97,
8027-8032.
|
|
|
|
|
|
|
A.R.Hoffmaster,
and
T.M.Koehler
(1999).
Autogenous regulation of the Bacillus anthracis pag operon.
|
| |
J Bacteriol, 181,
4485-4492.
|
|
|
|
|
|
|
A.Zitzer,
O.Zitzer,
S.Bhakdi,
and
M.Palmer
(1999).
Oligomerization of Vibrio cholerae cytolysin yields a pentameric pore and has a dual specificity for cholesterol and sphingolipids in the target membrane.
|
| |
J Biol Chem, 274,
1375-1380.
|
|
|
|
|
|
|
B.Vécsey-Semjén,
S.Knapp,
R.Möllby,
and
F.G.van der Goot
(1999).
The staphylococcal alpha-toxin pore has a flexible conformation.
|
| |
Biochemistry, 38,
4296-4302.
|
|
|
|
|
|
|
C.Neyt,
and
G.R.Cornelis
(1999).
Insertion of a Yop translocation pore into the macrophage plasma membrane by Yersinia enterocolitica: requirement for translocators YopB and YopD, but not LcrG.
|
| |
Mol Microbiol, 33,
971-981.
|
|
|
|
|
|
|
F.Brossier,
M.Mock,
and
J.C.Sirard
(1999).
Antigen delivery by attenuated Bacillus anthracis: new prospects in veterinary vaccines.
|
| |
J Appl Microbiol, 87,
298-302.
|
|
|
|
|
|
|
G.Anderluh,
A.Barlic,
Z.Podlesek,
P.Macek,
J.Pungercar,
F.Gubensek,
M.L.Zecchini,
M.D.Serra,
and
G.Menestrina
(1999).
Cysteine-scanning mutagenesis of an eukaryotic pore-forming toxin from sea anemone: topology in lipid membranes.
|
| |
Eur J Biochem, 263,
128-136.
|
|
|
|
|
|
|
G.Tang,
and
S.H.Leppla
(1999).
Proteasome activity is required for anthrax lethal toxin to kill macrophages.
|
| |
Infect Immun, 67,
3055-3060.
|
|
|
|
|
|
|
K.E.Beauregard,
S.Wimer-Mackin,
R.J.Collier,
and
W.I.Lencer
(1999).
Anthrax toxin entry into polarized epithelial cells.
|
| |
Infect Immun, 67,
3026-3030.
|
|
|
|
|
|
|
L.B.Price,
M.Hugh-Jones,
P.J.Jackson,
and
P.Keim
(1999).
Genetic diversity in the protective antigen gene of Bacillus anthracis.
|
| |
J Bacteriol, 181,
2358-2362.
|
|
|
|
|
|
|
M.Shtilerman,
G.H.Lorimer,
and
S.W.Englander
(1999).
Chaperonin function: folding by forced unfolding.
|
| |
Science, 284,
822-825.
|
|
|
|
|
|
|
M.Varughese,
A.V.Teixeira,
S.Liu,
and
S.H.Leppla
(1999).
Identification of a receptor-binding region within domain 4 of the protective antigen component of anthrax toxin.
|
| |
Infect Immun, 67,
1860-1865.
|
|
|
|
|
|
|
N.Li,
M.Erman,
W.Pangborn,
W.L.Duax,
C.M.Park,
J.Bruenn,
and
D.Ghosh
(1999).
Structure of Ustilago maydis killer toxin KP6 alpha-subunit. A multimeric assembly with a central pore.
|
| |
J Biol Chem, 274,
20425-20431.
|
|
|
PDB code:
|
|
|
|
|
|
|
|
N.M.Cirino,
D.Sblattero,
D.Allen,
S.R.Peterson,
J.D.Marks,
P.J.Jackson,
A.Bradbury,
and
B.E.Lehnert
(1999).
Disruption of anthrax toxin binding with the use of human antibodies and competitive inhibitors.
|
| |
Infect Immun, 67,
2957-2963.
|
|
|
|
|
|
|
O.Shatursky,
A.P.Heuck,
L.A.Shepard,
J.Rossjohn,
M.W.Parker,
A.E.Johnson,
and
R.K.Tweten
(1999).
The mechanism of membrane insertion for a cholesterol-dependent cytolysin: a novel paradigm for pore-forming toxins.
|
| |
Cell, 99,
293-299.
|
|
|
|
|
|
|
P.Quertenmont,
C.Wolff,
R.Wattiez,
P.Vander Borght,
P.Falmagne,
J.M.Ruysschaert,
and
V.Cabiaux
(1999).
Structure and topology of diphtheria toxin R domain in lipid membranes.
|
| |
Biochemistry, 38,
660-666.
|
|
|
|
|
|
|
R.J.Collier
(1999).
Mechanism of membrane translocation by anthrax toxin: insertion and pore formation by protective antigen
|
| |
J Appl Microbiol, 87,
283.
|
|
|
|
|
|
|
R.J.Gilbert,
J.L.Jiménez,
S.Chen,
I.J.Tickle,
J.Rossjohn,
M.Parker,
P.W.Andrew,
and
H.R.Saibil
(1999).
Two structural transitions in membrane pore formation by pneumolysin, the pore-forming toxin of Streptococcus pneumoniae.
|
| |
Cell, 97,
647-655.
|
|
|
|
|
|
|
R.Liddington,
A.Pannifer,
P.Hanna,
S.Leppla,
and
R.J.Collier
(1999).
Crystallographic studies of the anthrax lethal toxin
|
| |
J Appl Microbiol, 87,
282.
|
|
|
|
|
|
|
S.H.Leppla,
N.Arora,
and
M.Varughese
(1999).
Anthrax toxin fusion proteins for intracellular delivery of macromolecules
|
| |
J Appl Microbiol, 87,
284.
|
|
|
|
|
|
|
W.I.Lencer,
T.R.Hirst,
and
R.K.Holmes
(1999).
Membrane traffic and the cellular uptake of cholera toxin.
|
| |
Biochim Biophys Acta, 1450,
177-190.
|
|
|
|
|
|
|
Y.Singh,
K.R.Klimpel,
S.Goel,
P.K.Swain,
and
S.H.Leppla
(1999).
Oligomerization of anthrax toxin protective antigen and binding of lethal factor during endocytic uptake into mammalian cells.
|
| |
Infect Immun, 67,
1853-1859.
|
|
|
|
|
|
|
D.B.Lacy,
and
R.C.Stevens
(1998).
Unraveling the structures and modes of action of bacterial toxins.
|
| |
Curr Opin Struct Biol, 8,
778-784.
|
|
|
|
|
|
|
E.Schnepf,
N.Crickmore,
J.Van Rie,
D.Lereclus,
J.Baum,
J.Feitelson,
D.R.Zeigler,
and
D.H.Dean
(1998).
Bacillus thuringiensis and its pesticidal crystal proteins.
|
| |
Microbiol Mol Biol Rev, 62,
775-806.
|
|
|
|
|
|
|
H.L.Andrews,
J.P.Vogel,
and
R.R.Isberg
(1998).
Identification of linked Legionella pneumophila genes essential for intracellular growth and evasion of the endocytic pathway.
|
| |
Infect Immun, 66,
950-958.
|
|
|
|
|
|
|
J.Wesche,
J.L.Elliott,
P.O.Falnes,
S.Olsnes,
and
R.J.Collier
(1998).
Characterization of membrane translocation by anthrax protective antigen.
|
| |
Biochemistry, 37,
15737-15746.
|
|
|
|
|
|
|
M.Palmer,
I.Vulicevic,
P.Saweljew,
A.Valeva,
M.Kehoe,
and
S.Bhakdi
(1998).
Streptolysin O: a proposed model of allosteric interaction between a pore-forming protein and its target lipid bilayer.
|
| |
Biochemistry, 37,
2378-2383.
|
|
|
|
|
|
|
M.Varughese,
A.Chi,
A.V.Teixeira,
P.J.Nicholls,
J.M.Keith,
and
S.H.Leppla
(1998).
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies.
|
| |
Mol Med, 4,
87-95.
|
|
|
|
|
|
|
P.Boquet,
P.Munro,
C.Fiorentini,
and
I.Just
(1998).
Toxins from anaerobic bacteria: specificity and molecular mechanisms of action.
|
| |
Curr Opin Microbiol, 1,
66-74.
|
|
|
|
|
|
|
C.Lesieur,
B.Vécsey-Semjén,
L.Abrami,
M.Fivaz,
and
F.Gisou van der Goot
(1997).
Membrane insertion: The strategies of toxins (review).
|
| |
Mol Membr Biol, 14,
45-64.
|
|
|
|
|
|
|
E.Gouaux
(1997).
Channel-forming toxins: tales of transformation.
|
| |
Curr Opin Struct Biol, 7,
566-573.
|
|
|
|
|
|
|
H.Bayley
(1997).
Toxin structure: part of a hole?
|
| |
Curr Biol, 7,
R763-R767.
|
|
|
|
|
|
|
J.Rossjohn,
S.C.Feil,
W.J.McKinstry,
R.K.Tweten,
and
M.W.Parker
(1997).
Structure of a cholesterol-binding, thiol-activated cytolysin and a model of its membrane form.
|
| |
Cell, 89,
685-692.
|
|
|
PDB code:
|
|
|
|
|
|
|
The most recent references are shown first.
Citation data come partly from CiteXplore and partly
from an automated harvesting procedure. Note that this is likely to be
only a partial list as not all journals are covered by
either method. However, we are continually building up the citation data
so more and more references will be included with time.
Where a reference describes a PDB structure, the PDB
codes are
shown on the right.
|
|
Links
